Cyclacel pharmaceuticals announces preclinical proof-of-concept data for fadraciclib to be presented at the american association for cancer research (aacr) annual meeting 2024

Data support ongoing development program of novel cdk2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma data support ongoing development program of novel cdk2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma

CYCC Ratings Summary

CYCC Quant Ranking